featured-image

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on at to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, , will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related bloodstream infections.

A question and answer period will follow management's discussion. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok and LYMPHIRTM.



In , Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset.

LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius compl.

Back to Health Page